Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypericin photodynamic therapy in superficial bladder carcinoma
2007-001302-25Phase 2Completed
- Sponsor
- Laboratory for Pharmaceutical Biology (KU Leuven)
- Start
- Sep 2009
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hypericin in bladder cancer, transitional cell carcinoma (TCC) and Bladder cancer in situ (CIS), sponsored by Laboratory for Pharmaceutical Biology (KU Leuven). Started Sep 2009; status: completed.
02
Drugs
hypericin
03
Conditions
bladder cancertransitional cell carcinoma (TCC)Bladder cancer in situ (CIS)
Beyond the preview
Go deeper on 2007-001302-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001302-25.